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Abstract
Objectives: Mitochondrial methionyl-tRNA formyltransferase (MTFMT) is
required for the initiation of translation and elongation of mitochondrial
protein synthesis. Pathogenic variants in MTFMT have been associated with
Leigh syndrome (LS) and mitochondrial multiple respiratory chain deficien-
cies. We sought to elucidate the spectrum of clinical, neuroradiological and
molecular genetic findings of patients with bi-allelic pathogenic variants in
MTFMT. Methods: Retrospective cohort study combining new cases and pre-
viously published cases. Results: Thirty-eight patients with pathogenic vari-
ants in MTFMT were identified, including eight new cases. The median age
of presentation was 14 months (range: birth to 17 years, interquartile range
[IQR] 4.5 years), with developmental delay and motor symptoms being the
most frequent initial manifestation. Twenty-nine percent of the patients sur-
vived into adulthood. MRI headings in MTFMT pathogenic variants included
symmetrical basal ganglia changes (62%), periventricular and subcortical
white matter abnormalities (55%), and brainstem lesions (48%). Isolated
complex I and combined respiratory chain deficiencies were identified in
31% and 59% of the cases, respectively. Reduction of the mitochondrial
complex I and complex IV subunits was identified in the fibroblasts (13/13).
Sixteen pathogenic variants were identified, of which c.626C>T was the most
common. Seventy-four percent of the patients were alive at their last clinical
review (median 6.8 years, range: 14 months to 31 years, IQR 14.5 years).
Interpretation: Patients that harbour pathogenic variants in MTFMT have a
milder clinical phenotype and disease progression compared to LS caused by
other nuclear defects. Fibroblasts may preclude the need for muscle biopsy,
to prove causality of any novel variant.
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Introduction
Leigh syndrome (LS) is one of the most common paedi-
atric mitochondrial disorders, with a prevalence of
1:32,000–40,000.1 It is a progressive neurodegenerative
disorder commonly characterized by the onset of symp-
toms such as hypotonia, spasticity or developmental delay
between the ages of 3 and 12 months, with 83% of the
patients presenting before the age of 2 years.2,3 To date,
pathogenic variants in more than 80 genes have been
shown to cause LS although these only account for
approximately one half of all cases of the disease.4,5 The
survival of patients with LS is typically poor, with a med-
ian survival of 2.4 years.3
In 2011, Tucker and co-workers identified three patients
from two unrelated families with segregating, compound
heterozygous variants in MTFMT who presented with LS.6
The mitochondrial methionyl-tRNA formyltransferase
(MTFMT) gene encodes the mitochondrial protein of the
same name, which is required for the initiation of translation
of mtDNA-encoded proteins. MTFMT is responsible for
formylating Met-tRNAMet; in mammalian mitochondria,
there is only a single Met-tRNA, so the ratio of fMet-tRNAMet
(for initiation) to Met-tRNAMet (for translation elongation)
must be tightly controlled.7 MTFMT deficiency can therefore
cause impaired mitochondrial protein synthesis resulting in
multiple respiratory chain deficiencies. Further cases have
since been described, including a report of the phenotypic
spectrum of 11 patients with proven pathogenic variants in
MTFMT.8
In this study, we report eight new cases with bi-allelic
MTFMT variants. By combining our patients with other
previously reported cases, we sought to elucidate the full
spectrum of clinical, radiological and molecular genetics
findings, and evaluate the survival status of individuals
with MTFMT-related mitochondrial disease.
Methods
Subjects
New patients and additional data from previously pub-
lished cases were identified from the clinical and diagnos-
tic centers with expertise in mitochondrial disease across
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Europe (UK, Poland, and Netherlands), Australia and
USA. Clinical, radiological and molecular genetic data
were captured using a standardized pro forma. This study
was performed in accordance with the World Medical
Association’s Declaration of Helsinki and research and
ethical guidelines issued by each institution. A systematic
review of the available literature was conducted to ascer-
tain previously published cases. Authors of previously
published cases were contacted to provide additional clin-
ical and neuroimaging data (that were missing).
Histochemistry, quadruple
immunohistochemistry and immunoblotting
Tissue obtained from muscle biopsies was subjected to his-
tochemical analysis through the use of cytochrome c oxi-
dase (COX), succinate dehydrogenase (SDH) and
sequential COX/SDH reactions to allow analysis of COX-
deficient fibers as a marker of mitochondrial respiratory
chain deficiency (P1-4).9 For patients six to nine, histoen-
zymatic methods for assessment of the activities of individ-
ual mitochondrial respiratory chain complexes in muscle
were employed as previously described.10 Quadruple
immunofluorescent histochemical analysis, as described
elsewhere,11 was performed on a muscle biopsy (P3). Wes-
tern blotting was performed in one patient (P5) using pub-
lished protocols.6
Biochemical analysis
Mitochondrial respiratory chain complex activities were
determined spectrophotometrically using patient skeletal
muscle homogenates (P1-4; P6-9; P11-14) and fibroblasts
(P5) as previously described.12–14
Identification of pathogenic MTFMT variants
The majority of the patients were diagnosed via exome
sequencing or a custom MitoExome panel.6,15–17 Two
patients were diagnosed using a custom Ampliseq panel
and Ion Torrent PGM sequencing and direct sequencing
of MTFMT, respectively. All MTFMT variants detected by
NGS methodologies were confirmed using Sanger
sequencing; variant nomenclature is according to Gen-
Bank Accession Number NM_139242.3.
Statistical analysis
To determine putative predictors of survival, Kaplan-
Meier analysis and Cox-regression analysis were applied.
All analyses were performed using SPSS software (V 22.0)
and Minitab (V 17). The significance level was deter-
mined at ≤ 0.05 level.
Results
Patients
Thirty-eight patients with known variants in MTFMT
were identified: eight new cases (P1,2,5,6,7,8,10,11), nine
previously published cases with additional clinical infor-
mation (P3,4,9,12,13,14,15,16,17), and a further 21
patients were identified through the literature search
(Table S1). Clinical data were available for further analysis
in 34 patients (Table 1). A clinical synopsis for 10
patients is available in Data S1.
Disease onset and presenting symptoms
The median age of onset was 14 months (range: birth to
17 years, interquartile range: 4.5 years). Twenty patients
(59%) had developmental delay or regression at presenta-
tion: global psychomotor delay involving motor move-
ment and speech (n = 12), motor delay (n = 5), speech
delay (n = 2) and developmental regression only (n = 1).
Two patients presented with autism spectrum disorder.
Sixteen patients (47%) presented with motor symptoms,
including motor delay, gait instability, hypotonia and
Table 1. Summary of clinical features (n = 34).
Previously
reported
New
cases Total
No of individuals; pedigrees 26; 23 8; 8 34; 31
Prenatal/Antenatal
Premature 5 1 6
SGA 4 3 7
Pathological signs at birth 4 3 7
Microcephaly 7 3 10
Hypospadias 0 3 3
Developmental delay/regression 20 7 27
Seizures 3 3 6
Gait abnormality 14 5 19
Hypotonia 11 6 17
Abnormal reflexes 12 4 16
Dystonia 5 3 8
Tremor1 4 0 4
Ocular features 14 6 20
Feeding difficulties 4 6 10
Respiratory problems 4 6 10
Cardiac dysfunction 12 5 17
Lactic acidosis 19 8 27
Acute exacerbations 15 5 20
ITU admission 6 4 10
SGA, small for gestational age. Ocular features included nystagmus,
strabismus, decreased visual acuity, ophthalmoplegia and gaze palsies.
Respiratory problems included apnoea, hypoventilation and hyperven-
tilation.
1One patient (P14 in Table S1) exhibited the triad of Parkinsonism.
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 517
H. Hayhurst et al. MTFMT-Related Mitochondrial Disease
weakness. A third of the patients presented with ocular
symptoms including nystagmus, strabismus and optic
atrophy. Ten patients (29%) had feeding difficulties.
Clinical features throughout disease course
Ninety-four percent of (32 of 34) the patients demon-
strated abnormal motor findings throughout their disease
course (Table 1). Two patients had features of Parkinson-
ism including tremor, bradykinesia, rigidity, paucity of
facial expressions and poverty of gait (Patients 14 and
25).8,18 Axonal, sensory neuropathy was identified in one
patient. The assessment of mobility was available for 15
patients; nine patients (60%) were still ambulatory
(unaided) during their clinic assessment (mean age
17  9 years, range 6–31 years).
Ocular symptoms were present in 20 patients (59%):
strabismus including subacute, unilateral gaze palsy
(n = 10), nystagmus (n = 7), optic atrophy (n = 4),
reduced visual acuity (n = 4), ptosis (n = 2), pigmentary
degeneration of retina (n = 1) and hemianopia (n = 1).
Six patients (17%) had epilepsy; these included focal sei-
zures, generalized tonic–clonic seizures and convulsive
status epilepticus.
Twenty-four out of 29 (83%) had elevated serum lac-
tate (83%) (range 2.7 to 14.3 mmol/L, nor-
mal < 2.2 mmol/L). For the 24 patients with reported
CSF lactate levels, 23 patients (96%) had elevated levels
(range 3.3–7.8 mmol/L, normal < 2.2 mmol/L). Eighteen
of 34 patients (53%) had documented abnormal cardiac
findings. Structural cardiac abnormalities were identified
in 12 patients: hypertrophic cardiomyopathy (n = 7),
ventricular septal defects (VSD) (n = 3), noncompaction
cardiomyopathy (n = 1), pulmonary stenosis (n = 1) and
aortic regurgitation (n = 1). One patient had both aortic
regurgitation and a VSD. Abnormal cardiac rhythm and
conduction abnormalities were reported in five patients:
Wolff–Parkinson–White syndrome (n = 3), symptomatic
sinus tachycardia (n = 1), and supraventricular tachycar-
dia (n = 1). Two patients developed bradycardia con-
comitantly with the apnoeic episodes, likely secondary to
the subacute brainstem dysfunction related to LS.
Acute decompensation requiring hospital
admission
Fifty-nine percent of patients (20 of 34) had acute exacer-
bations/decompensation requiring hospital admission
throughout their disease course, and ten patients who had
acute exacerbations required admission to an intensive
care unit (ICU) setting. Fifty-five percent of decompensa-
tions (n = 11) were due to respiratory complications.
Infections accounted for acute hospital admissions in ten
patients, gait disturbance in six, seizures in five and poor
nutrition/dehydration in three patients. One patient mani-
fested with subacute onset of arm and chest pain, with
MRI of whole spine showing intrinsic cord signal abnor-
malities (Fig. 1) that partially resolved clinically and radio-
logically with supportive treatment only.
Neuroimaging
Neuroimaging data were available for 33 patients (Table 2
and Fig. 1). In the 19 patients with white matter changes,
12 also had changes in the basal ganglia. Among the five
patients who had spinal imaging, three had intrinsic cer-
vical and/or thoracic spinal cord signal changes. In one
patient, the rarefaction of white matter was accompanied
by cavitating lesions with peripheral enhancement in the
centrum semiovale (Fig. 1).
Six patients (18%) had neither basal ganglia nor brain-
stem abnormalities even though their clinical presentation
and disease trajectory was consistent with LS (P1, P19,
P24, P28, P31 and P37). Four of these patients had exten-
sive white matter abnormalities identified on MRI head
(P1, P24, P28 and P31), one had a normal MRI head and
MR spectroscopy at the age of 4 years (P37), and one
patient had multiple ischaemic stroke changes with neu-
rovascular imaging showing changes suggestive of Moya-
moya disease (P19).19 The median age of patients with
either basal ganglia or brainstem abnormalities was signif-
icantly older than those without any changes (16.5 vs.
5 years, P = 0.04).
Evaluation of respiratory chain complexes
in muscle biopsy and fibroblasts
Twenty six of 28 patients (89%) with available muscle
biopsies had evidence of respiratory chain deficiency
(Fig. 2). Of these, complex I was decreased in all
patients. Patterns of respiratory chain deficiency were as
follows: isolated complex I deficiency (n = 9) and multi-
ple respiratory chain deficiencies (n = 17). Complex I
enzymatic activity was more severely decreased, com-
pared to other complexes8 (Fig. 2C); this observation
was corroborated with the findings of quadruple
immunohistochemistry in one muscle biopsy where loss
of complex I (NDUFB8) protein was more pronounced
than loss of complex IV (COXI) protein (Fig. 2D).
Three patients had muscle biopsies demonstrating no
definite respiratory chain deficiency. Immunoblotting
was performed in fibroblasts derived from 13 patients,
identifying a quantitative loss of complex I and IV sub-
units in all cases (western blot of P5’s fibroblasts is
shown in Fig. 2E). Biochemical analysis of the OXPHOS
enzymatic function in fibroblasts showed that the
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deficiency was more marked in complex I than complex
IV for six of the seven cases tested.6,8
MTFMT pathogenic variants
Of the 38 patients in this cohort, 30 were compound
heterozygous and eight were homozygous for pathogenic
MTFMT variants. There were 16 pathogenic variants: fra-
meshift (n = 6), missense (n = 5) and nonsense (n = 5)
(Fig. 3A). The c.626C>T is the most common variant,
which has been identified in half of all cases. Homozygos-
ity of c.626C>T was identified in seven patients; there was
no report of consanguinity in any family with the excep-
tion of one patient in which the family history was not
explicitly stated. The c.626C>T variant lies in exon 4, and
predominantly results in the skipping of this exon by
abolishing exonic splicing enhancers and/or by generating
an exonic splicing suppressor.6 Skipping of exon 4 results
in a frameshift and premature truncation of MTFMT
Figure 1. MRI head and cervical cord. T2-weighted axial views show symmetrical hyperintensities in the striatum (A) (P4), hyperintensities in
bilateral putamen, right caudate nucleus and a small white matter change in the left genu of corpus callosum (arrow) (B) (P2). T2-weighted
sagittal view shows an intrinsic T2 hyperintensity spanning C1-4 level (C), with a corresponding change identified on the axial view (D) (P3).
Extensive T2-hyperintensities with areas of cavitation seen in the genu and splenium of the corpus callosum (E) and the posterior periventricular
white matter with restricted diffusion, but not within the areas of cavitation (arrows) (F). (G) Large cystic changes with surrounding hyperintense
T2 signal abnormality are present in the deep white matter. T1-weighted sagittal view shows the confluent signal abnormality of the corpus
callosum (H) (P1).
Table 2. Summary of cranial MRI findings (n = 33).
Imaging findings (n = 33) Frequency (%)
Caudate 12 (36)
Putamen 18 (55)
Globus pallidus 10 (30)
Any part of basal ganglia 21 (64)
Midbrain 14 (42)
Pons 4 (12)
Medulla 5 (15)
Any part of brainstem 16 (48)
Basal ganglia and brainstem changes 10 (30)
Corpus callosum 10 (30)
White matter changes 18 (55)
Patchy, non-specific 14 (42)
Leukodystrophy 4 (12)
Crus cerebri 4 (12)
Spinal cord (n = 5) 3 (60)
Note only five patients had imaging of their spinal cord performed or
commented.
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(p.Arg181Serfs*6). A small amount of residual full-length
transcript is also produced where the c.626C>T variant
encodes a protein with a p.Ser209Leu missense mutation.6
The explanation of amino acid nomenclature p.Arg181-
Serfs*6 is provided in the Figure S1.
Survival status
Twenty five of 34 patients (74%) were alive at the time of
their last follow-up (median 6.8 years, range: 14 months
to 31 years, IQR: 14.5 years). The median age of death
was 2.9 years (range: 14 months to 17 years, IQR: 9.45).
The cause of death was known for five patients: general-
ized seizure (n = 1), pneumonia (n = 1), respiratory
arrest (n = 1), cardiac arrhythmia (n = 1) and one
patient died from an intracranial hemorrhage following a
cardiac surgery. There was no statistical difference in sur-
vival status among three genetic subgroups: homozygous
c.626C>T (n = 8), compound heterozygous c.626C>T
(n = 13) and others (n = 13) (P = 0.744) (Fig. 3B). A
history of ICU admission appeared to be associated with
a poorer survival; however, this finding did not reach
(A) (B)
(C) (D) (E)
Figure 2. Histopathological and biochemical analyses of patient muscle biopsies. (A and B) Histopathological analysis of patient skeletal muscle
sections showing hematoxylin and eosin (H&E) staining (i), cytochrome c oxidase (COX) histochemistry (ii), succinate dehydrogenase (SDH)
histochemistry (iii) and sequential COX-SDH histochemistry (iv) for P3 (A) and P4 (B) respectively; the COX defect is generalized but only weakly
demonstrated histochemically. Scale bar = 50 lm (C) Respiratory chain enzyme activity measurements in skeletal muscle from P1, P2, P3 and P4
demonstrate a combined enzyme defect involving complexes I and IV in all four patients compared to age-matched controls. (D) Respiratory chain
profile following quadruple oxidative phosphorylation immunofluorescence analysis of cryosectioned muscle from P4, confirming the presence of
fibers lacking complex I (NDUFB8) protein, and to a lesser extent, complex IV (COXI) protein. Each dot represents the measurement from an
individual muscle fiber, color-coded according to its mitochondrial mass (blue-low, normal-beige, high-orange, very high-red). Dashed lines
indicate SD limits for the classification of fibers. Lines next to x- and y-axes represent the levels (SDs from the average of control fibers after
normalization to porin/VDAC1 levels; _z= Z-score, see Methods section of Rocha et al. 2015 for full description of statistics (https://www.ncbi.
nlm.nih.gov/pubmed/26469001)) of NDUFB8 and COX1 respectively: (beige = normal (>3), light beige = intermediate positive (3 to4.5), light
purple = intermediate negative (4.5 to 6), purple = deficient (<6). Bold dotted lines indicate the mean expression level observed in
respiratory-normal muscle fibers. (E) Western blot of protein from fibroblasts showed reduced levels of complex I (CI) and complex IV (CIV)
subunits in P5 relative to controls. Complex II subunit SDHB is indicative of loading. DT45 and LS1 were used as positive controls; DT45 has
isolated complex I deficiency and mutations in NDUFAF6, and LS1 has isolated complex IV deficiency and mutations in PET100.
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statistical significance (P = 0.052, Log-Rank) (Fig. 3C).
Other factors such as sex, seizures, imaging changes such
as abnormalities of basal ganglia or brainstem, cardiac
dysfunction, respiratory problems were not predictors of
survival.
Discussion
A recent multi-center study in LS showed that the median
age of onset was 7 months and nearly 40% of the patients
died by the time of data analysis with median age of
death being 2.4 years.3 In this retrospective, observational
study, we demonstrate that patients with pathogenic
MTFMT variants may have a later age of onset (median
14 months, range: birth to 17 years), with three patients
presenting in their teenage years. Lactic acidosis, develop-
mental delay, abnormal ocular findings and gait abnor-
malities were among the most common clinical findings.
Abnormal cardiac investigations were identified in 53% of
the patients and cardiomyopathy appeared to be the most
common finding (35%). Furthermore, the survival rate
appears higher in patients with MTFMT-related mito-
chondrial disease with ~30% of the patients currently in
their adulthood and ~25% died under the age of 21, com-
pared to the previous cohort study.3 The rates of acute
exacerbation and admission to ICU in our cohort were
comparable to other case series of LS3; of the 24 patients
who were documented to be alive, 14 of these had epi-
sodes of acute decompensation, and five had ICU admis-
sions. This is particularly remarkable as LS is often
associated with a rapid decline and poor prognosis, with
death commonly occurring in preschool years.
Bilateral, symmetrical T2-weighted hyperintensities of
the basal ganglia and/or brainstem, are considered hall-
marks of the syndrome and form part of the diagnostic
criteria.20 Our findings show that 36% of the patients
with MTFMT pathogenic variants did not have the typical
basal ganglia signal abnormalities. Moreover, brainstem
abnormalities were identified in only half of the patients.
Around 20% of the patients had neither basal ganglia nor
Figure 3. (A) Pathogenic variants in MTFMT. Sixteen pathogenic variants have been identified. The percentage in each bracket represents the
frequency of a given pathogenic variant out of 76 alleles. Figure 3 (B) and (C) Survival Curves. Kaplan-Meier curves show that no statistical
difference in survival was observed in three different genotypic groups (B). Patients with a past history of ICU admission showed a nonsignificant
trend towards shorter survival time when compared to those without ICU admission (P = 0.052, Log-Rank) (C).
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brainstem lesions noted. When present, MRI scans of the
spine showed long, intrinsic signal abnormalities in the
cervical and/or thoracic cord. However these were not
routinely performed, only when patients presented with
subacute spinal cord syndrome. They indicate that meta-
bolic decompensation can also occur in spinal cord in
addition to basal ganglia and brainstem, as shown in
other mitochondrial genetic defects as well as postmortem
spinal cord tissue from patients with LS.21,22 White mat-
ter changes ranging from patchy changes to symmetrical,
confluent subcortical white matter signal abnormality
(leukodystrophy) were present in 55% of the patients pre-
sented here. The underlying neurobiological mechanism
remains elusive as no neuropathological study is available
to date. However, given MTFMT plays a part in one-car-
bon metabolism, which requires folate as a key cofactor,
it seems plausible that there might be a mechanistic link
between MTFMT deficiency, oligodendrocyte dysfunction
and impaired myelination.23
MTFMT deficiency has been previously proposed to be
one of the common nuclear defects causing LS, and the
c.626C>T variant was thought to be a founder genetic
variant in the European population with a quoted allele
frequency of 0.11%.5,8 Interestingly, with the availability
of larger exome and genome sequencing data (Genome
Aggregation Database, gnomAD), the allele frequency for
the c.626C>T in the non-Finnish European population
has not changed markedly (89/126686, 0.07%) and this
variant has not been observed in the Ashkenazi Jewish,
East Asian and South Asian populations. It is, therefore,
unsurprising that at least six of the seven homozygous
c.626C>T patients were from non-consanguineous family
pedigrees. Indeed, SNP array data pertaining to case 5
(see Data S2) demonstrate a small region of homozygosity
(~90 kb) encompassing the c.626C>T variant (highlighted
pink) without evidence of additional large stretches of
homozygosity, consistent with a founder mutation
opposed to undisclosed consanguinity. We have not iden-
tified any significant difference in survival in different
pathogenic MTFMT variants, suggesting that genotype is
not a predictor for the disease trajectory. Studies using a
Mtfmt knockout mouse fibroblast model lacking exon 4
in MTFMT demonstrated that MTFMT is not an absolute
requirement for initiation of translation and elongation of
mitochondrial protein synthesis in mice but deficiency of
this protein results in reduced efficiency of this process
and downstream oxidative phosphorylation defects.24 This
may contribute to the overall milder disease course
observed in the MTFMT-related mitochondrial disease
presented here compared with typical LS.
Most of the patients in this case series had genomic
studies performed after muscle biopsy had already pro-
vided evidence of a respiratory chain complex I or
combined defect. However, current practice is increasingly
to perform genomic studies earlier after clinical presenta-
tion in order to avoid an invasive biopsy where possible.
For patients with MTFMT variants not previously linked
to disease it may be necessary to obtain functional evi-
dence to prove causality. Muscle biopsy can still be
avoided as immunochemical analysis with a respiratory
chain antibody cocktail demonstrated loss of complex I
and IV subunits in fibroblasts from all 13 patients in this
series studied in this way. That profile is shared by many
other defects of mitochondrial translation so it is worth
noting that almost all MTFMT patients reported to date
have had mutations that are expected to result in substan-
tial loss of MTFMT protein. Haack and colleagues showed
that fibroblasts from all five patients tested had markedly
decreased MTFMT on western blot, providing a specific
test for loss of function variants.8
We acknowledge the limitations of our study, including
the retrospective design and the variable follow-up of
patients resulting in incomplete clinical or biochemical
data for some cases. This, however, suggests that the fre-
quency of clinical symptoms described here is likely to be
an underestimation. Despite our best effort of enrolling
new patients and previously reported cases in the regres-
sion analysis, we have not been able to identify any signif-
icant predictors for the survival.
In conclusion, our findings demonstrate that patients
with pathogenic variants in MTFMT present at a rela-
tively older age and exhibit a milder disease trajectory
with 29% of the patients surviving into adulthood, com-
pared to other nuclear genetic defects that cause LS. Eigh-
teen percent of the patients exhibited a classical clinical
course without typical radiological findings of LS, high-
lighting that this condition may still be under-recognized.
Fibroblasts may preclude the need for muscle biopsy,
when novel variants are identified, to confirm the
pathogenicity.
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the Supporting Information section at the end of the article.
Figure S1. Explanation for the change in MTFMT muta-
tion nomenclature.
Table S1. Summary of eight new cases (P1,2,5,6,7,8,10,11)
and 30 other previously reported patients.
Data S1. Clinical vignettes (Patients 1-14)
Data S2. SNP array data demonstrate a small region of
homozygosity (~90kb) encompassing the c.626C>T vari-
ant (highlighted pink) without evidence of additional
large stretches of homozygosity.
524 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
MTFMT-Related Mitochondrial Disease H. Hayhurst et al.
